Venus Remedies Limited (VENUSREM) - Net Assets
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has net assets worth Rs5.94 Billion INR (≈ $64.27 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs7.68 Billion ≈ $83.07 Million USD) and total liabilities (Rs1.74 Billion ≈ $18.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Venus Remedies Limited (VENUSREM) total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs5.94 Billion |
| % of Total Assets | 77.37% |
| Annual Growth Rate | 16.29% |
| 5-Year Change | 40.14% |
| 10-Year Change | 28.18% |
| Growth Volatility | 24.05 |
Venus Remedies Limited - Net Assets Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's net assets have evolved over time, based on quarterly financial data. Check Venus Remedies Limited tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Venus Remedies Limited (2006–2025)
The table below shows the annual net assets of Venus Remedies Limited from 2006 to 2025. For live valuation and market cap data, see Venus Remedies Limited (VENUSREM) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs5.61 Billion ≈ $60.66 Million |
+15.05% |
| 2024-03-31 | Rs4.88 Billion ≈ $52.73 Million |
+5.91% |
| 2023-03-31 | Rs4.60 Billion ≈ $49.78 Million |
+4.52% |
| 2022-03-31 | Rs4.40 Billion ≈ $47.63 Million |
+10.03% |
| 2021-03-31 | Rs4.00 Billion ≈ $43.29 Million |
+23.79% |
| 2020-03-31 | Rs3.23 Billion ≈ $34.97 Million |
-2.75% |
| 2019-03-31 | Rs3.33 Billion ≈ $35.96 Million |
-8.12% |
| 2018-03-31 | Rs3.62 Billion ≈ $39.14 Million |
-19.86% |
| 2017-03-31 | Rs4.52 Billion ≈ $48.84 Million |
+3.19% |
| 2016-03-31 | Rs4.38 Billion ≈ $47.33 Million |
-4.17% |
| 2015-03-31 | Rs4.57 Billion ≈ $49.39 Million |
-1.07% |
| 2014-03-31 | Rs4.62 Billion ≈ $49.92 Million |
+21.76% |
| 2013-03-31 | Rs3.79 Billion ≈ $41.00 Million |
+23.38% |
| 2012-03-31 | Rs3.07 Billion ≈ $33.23 Million |
+29.70% |
| 2011-03-31 | Rs2.37 Billion ≈ $25.62 Million |
+38.40% |
| 2010-03-31 | Rs1.71 Billion ≈ $18.51 Million |
+23.51% |
| 2009-03-31 | Rs1.39 Billion ≈ $14.99 Million |
+55.75% |
| 2008-03-31 | Rs889.86 Million ≈ $9.62 Million |
+61.41% |
| 2007-03-31 | Rs551.31 Million ≈ $5.96 Million |
+72.85% |
| 2006-03-31 | Rs318.96 Million ≈ $3.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Venus Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 215266100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs2.15 Billion | 38.38% |
| Common Stock | Rs133.70 Million | 2.38% |
| Other Comprehensive Income | Rs2.44 Billion | 43.50% |
| Other Components | Rs883.26 Million | 15.75% |
| Total Equity | Rs5.61 Billion | 100.00% |
Venus Remedies Limited Competitors by Market Cap
The table below lists competitors of Venus Remedies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jeju Bank
KO:006220
|
$229.00 Million |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
$229.07 Million |
|
Cloud Live Technology Group Co Ltd
SHE:002306
|
$229.09 Million |
|
Petron Malaysia Refining Marketing
KLSE:3042
|
$229.12 Million |
|
KOSES Co.Ltd
KQ:089890
|
$228.98 Million |
|
Ace Bed Company Limited
KQ:003800
|
$228.94 Million |
|
First Internet Bancorp
NASDAQ:INBK
|
$228.86 Million |
|
Shenzhen Auto Electric Power Plant Co Ltd
SHE:002227
|
$228.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Venus Remedies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,875,501,000 to 5,609,500,000, a change of 733,999,000 (15.1%).
- Net income of 453,200,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 285,648,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs453.20 Million | +8.08% |
| Other Comprehensive Income | Rs285.65 Million | +5.09% |
| Other Changes | Rs-4.85 Million | -0.09% |
| Total Change | Rs- | 15.05% |
Book Value vs Market Value Analysis
This analysis compares Venus Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 41.75x to 3.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs37.94 | Rs1584.10 | x |
| 2007-03-31 | Rs65.58 | Rs1584.10 | x |
| 2008-03-31 | Rs105.27 | Rs1584.10 | x |
| 2009-03-31 | Rs163.96 | Rs1584.10 | x |
| 2010-03-31 | Rs202.03 | Rs1584.10 | x |
| 2011-03-31 | Rs259.52 | Rs1584.10 | x |
| 2012-03-31 | Rs334.34 | Rs1584.10 | x |
| 2013-03-31 | Rs388.99 | Rs1584.10 | x |
| 2014-03-31 | Rs410.44 | Rs1584.10 | x |
| 2015-03-31 | Rs399.10 | Rs1584.10 | x |
| 2016-03-31 | Rs381.26 | Rs1584.10 | x |
| 2017-03-31 | Rs393.42 | Rs1584.10 | x |
| 2018-03-31 | Rs293.26 | Rs1584.10 | x |
| 2019-03-31 | Rs269.47 | Rs1584.10 | x |
| 2020-03-31 | Rs262.01 | Rs1584.10 | x |
| 2021-03-31 | Rs324.33 | Rs1584.10 | x |
| 2022-03-31 | Rs329.50 | Rs1584.10 | x |
| 2023-03-31 | Rs344.39 | Rs1584.10 | x |
| 2024-03-31 | Rs364.74 | Rs1584.10 | x |
| 2025-03-31 | Rs419.57 | Rs1584.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Venus Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.08%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.00%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.28x
- Recent ROE (8.08%) is below the historical average (14.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 50.69% | 19.07% | 1.36x | 1.95x | Rs129.77 Million |
| 2007 | 46.04% | 17.33% | 0.94x | 2.82x | Rs198.70 Million |
| 2008 | 40.24% | 16.40% | 1.05x | 2.34x | Rs269.11 Million |
| 2009 | 31.71% | 16.31% | 0.91x | 2.14x | Rs300.92 Million |
| 2010 | 23.11% | 12.57% | 0.90x | 2.05x | Rs224.41 Million |
| 2011 | 19.51% | 12.69% | 0.79x | 1.95x | Rs225.26 Million |
| 2012 | 15.32% | 11.49% | 0.71x | 1.87x | Rs163.48 Million |
| 2013 | 15.12% | 12.25% | 0.65x | 1.89x | Rs193.97 Million |
| 2014 | 13.93% | 11.99% | 0.64x | 1.81x | Rs181.36 Million |
| 2015 | 1.13% | 1.11% | 0.55x | 1.84x | Rs-405.08 Million |
| 2016 | 0.39% | 0.41% | 0.49x | 1.93x | Rs-420.64 Million |
| 2017 | 1.75% | 2.00% | 0.48x | 1.84x | Rs-372.51 Million |
| 2018 | -8.48% | -8.31% | 0.49x | 2.07x | Rs-668.83 Million |
| 2019 | -8.59% | -9.00% | 0.43x | 2.20x | Rs-618.27 Million |
| 2020 | -3.09% | -2.97% | 0.53x | 1.97x | Rs-423.36 Million |
| 2021 | 15.43% | 11.27% | 0.99x | 1.39x | Rs217.37 Million |
| 2022 | 9.25% | 6.80% | 1.03x | 1.32x | Rs-33.20 Million |
| 2023 | 5.77% | 4.78% | 0.92x | 1.31x | Rs-194.64 Million |
| 2024 | 5.84% | 4.82% | 0.94x | 1.29x | Rs-202.64 Million |
| 2025 | 8.08% | 7.00% | 0.91x | 1.28x | Rs-107.75 Million |
Industry Comparison
This section compares Venus Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $27,240,259,507
- Average return on equity (ROE) among peers: 16.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Venus Remedies Limited (VENUSREM) | Rs5.94 Billion | 50.69% | 0.29x | $229.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.17 Billion | 3.21% | 1.48x | $25.00 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $401.98 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $15.58 Billion | 12.42% | 0.44x | $662.50 Million |
| Abbott India Limited (ABBOTINDIA) | $8.33 Billion | 20.02% | 0.37x | $6.41 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $8.41 Billion | 36.84% | 0.36x | $4.75 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $1.13 Billion |
| Alkem Laboratories Limited (ALKEM) | $37.87 Billion | 19.58% | 0.46x | $7.38 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.26 Billion | 16.93% | 0.29x | $162.90 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $52.38 Billion | 9.95% | 0.36x | $1.71 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $138.92 Billion | 17.02% | 0.90x | $9.67 Billion |
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more